NEW YORK (GenomeWeb News) – Predictive Biosciences will offer its molecular diagnostic bladder cancer tests to Arup Laboratories' national network of clients under a deal announced today.
The non-exclusive agreement grants Salt Lake City-based Arup the rights to offer Predictive Bio's CertNDx Bladder Cancer Assays to hospitals, healthcare providers, academic medical centers, and military and government facilities around the country. Arup's clients will be able to order the test through the reference laboratory, while Predictive Bio will run the diagnostic testing in its CAP and CLIA-certified laboratory.
The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test for the evaluation of patients with hematuria and for the monitoring of bladder cancer recurrence after treatment. It stratifies patients based on their likelihood of bladder cancer and is also available as a tissue-based prognostic test for molecular grading.
"We believe this alliance will greatly expand the availability of our bladder cancer products to a wider network of leading medical facilities that can benefit from CertNDx testing," Predictive Bio CEO Pierre Cassigneul said in a statement.
Financial and other terms of the deal were not disclosed.